An Open Label Study With OHR/AVR118 in Advanced Cancer Patients with Anorexia-Cachexia.

Trial Profile

An Open Label Study With OHR/AVR118 in Advanced Cancer Patients with Anorexia-Cachexia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs AVR 118 (Primary)
  • Indications Anorexia; Cachexia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2013 Results have been reported in an Ohr Pharmaceutical media release.
    • 21 Mar 2013 Primary endpoint 'Bodyweight' (weight gain) has not been met according to an Ohr Pharmaceutical media release.
    • 26 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top